Details of the Drug Combination

General Information of Drug Combination (ID: DC49JTO)

Drug Combination Name
Miltefosine Pentoxifylline
Indication
Disease Entry Status REF
Leishmaniasis Phase 2 [1]
Component Drugs Miltefosine   DMND304 Pentoxifylline   DMU3DNC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Miltefosine
Disease Entry ICD 11 Status REF
Chronic urticaria N.A. Approved [2]
Leishmaniasis 1F54 Approved [3]
Visceral leishmaniasis 1F54.0 Phase 2 [4]
Miltefosine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phospholipase A2 (PLA2G1B) TT9V5JH PA21B_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Miltefosine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Choline phosphatase 1 (PLD1) DEB2ZMT PLD1_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Miltefosine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [8]
------------------------------------------------------------------------------------
Indication(s) of Pentoxifylline
Disease Entry ICD 11 Status REF
Alcoholic hepatitis DB94.1 Approved [5]
Intermittent claudication BD40.00 Approved [6]
Type-1 diabetes 5A10 Approved [5]
Peripheral vascular disease BD4Z Investigative [5]
Pentoxifylline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN . [9]
------------------------------------------------------------------------------------
Pentoxifylline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Pentoxifylline Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Increases ADR [11]
Perforin-1 (PRF1) OTFVXD7H PERF_HUMAN Increases ADR [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02530697) The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
2 Miltefosine FDA Label
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
5 Pentoxifylline FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7095).
7 Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20.
8 MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
9 Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
10 Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos. 1997 Dec;25(12):1354-8.
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.